DMAC vs LI · $157.4M cap vs P/E 24, rev $16.06B
DiaMedica Therapeutics Inc (DMAC) versus Li Auto Inc (LI) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Li Auto Inc (LI) is a auto manufacturers company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported LI revenue for 2025-12-31 was $16.06B. Net income was $162.9M. Revenue was down 18.8% from 2024-12-31 to 2025-12-31. LI currently screens at market cap $26.62B and trailing P/E 24.2.
DMAC currently screens at market cap $157.4M. LI currently screens at market cap $26.62B and trailing P/E 24.2.
Not investment advice. Open the DMAC and LI stock pages for the full models.
Not investment advice.